VTCN1 and neoplasm: Due to high expression level of B7S1 in OvCa was found significantly associated with tumor stage (Liang et al., 2016) and a worse progression-free survival (PFS) (Ye et al., 2018), B7S1 may serve as a promising candidate target for OvCa immunotherapy.